A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes

Abstract Molecular classification of the different nodal peripheral T-cell lymphoma (PTCL) entities is not yet clarified, and this particularly applies to the two main clinical subtypes: angio-immunoblastic T-lymphomas (AITL) and PTCL-not otherwise specified (PTCL-NOS). Previous studies have shown that these two entities bear distinct gene expression profiles (GEP) that allow their distinction. However, clinical usage of GEP has been limited due to its complexity and to the absence of a well validated signature. Following the recent advances in next generation sequencing (NGS), three recurrently mutated genes (RHOA , TET2 , DNMT3A ) were found in approximately 60-70% of AITL and in 20-30% of PTCL-NOS. In addition, 20-30% of AITLs cases are characterized by a hotspot IDH2R172 mutation that is generally absent in PTCL-NOSs. Furthermore, the interrelationship of the mutations with the AITL/PTCL-NOS GEP classification has not been comprehensively evaluated. We collected and analyzed GEP data from available public PTCL studies (for a total of 503 cases: 127 AITL, 144 PTCL-NOS, 56 ALK-pos anaplastic large cell lymphoma (ALCL), 96 Alk-neg ALCL, 21 adult T-lymphoma/leukemia (ATLL), 59 NK/T-cell lymphomas. After correcting for any potential batch effect, the cases were re-classified based on published studies (Iqbal, Blood 2014). For 53 cases, mutational data for RHOA , TET2 , DNMT3A, and IDH2 genes (Wang, Blood 2015) were available and used to perform an integrated analysis to improve the current molecular classification between AITL and PTCL-NOS. As expected, ALK-neg and ALK-pos ALCLs, NK/T-cell lymphoma and ATLL were associated with distinct signatures; conversely, GEP of AITL and PTCL-NOS revealed significant overlap. To improve their distinction, we investigated the contribution of recurrent mutations to the transcriptional pattern, applying a recently published analysis (Gerstung, Nat Comm 2015) on 39 AITLs and 14 PTCL-NOSs for whom mutational data were available. Briefly, we created a model that included the lymphoma histotype, its gene expression profile, its genotype, and the age and gender of the patient. Interestingly, we observed how the mutational status of RHOA , TET2 and DNMT3A correlated poorly with the transcriptional profile of each case in both AITL and PTCL-NOS. RHOA mutations are known to be frequently subclonal, possibly explaining their little effect on gene expression. Conversely, TET2 and DNMT3A mutations are likely as early as hematopoietic stem cells mutations involved in clonal hemopoiesis, so that their effect on transcription may be lost during lymphoma development. Conversely, a strong transcriptional signature was identified in IDH2R172 samples consisting of 35 genes with False Discovery Rate (FDR) In this study, we provide a novel and reproducible bioinformatic approach to integrate clinical, expression and mutational data to improve the current molecular classification of PTCL. The presence of IDH2R217 mutations and the extent of PC infiltration could be used to differentiate AITL and PTCL-NOS in clinical practice, and this will be tested in future studies. Disclosures Chiappella: Pfizer: Speakers Bureau; Teva: Speakers Bureau; Amgen: Speakers Bureau; Celgene: Speakers Bureau; Roche: Speakers Bureau; Janssen: Speakers Bureau; Nanostring: Speakers Bureau. Zaja: Takeda: Honoraria; Janssem: Honoraria; Abbvie: Honoraria; Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria. Corradini: Amgen: Honoraria; Sanofi: Honoraria; Takeda: Honoraria; Janssen: Honoraria; Celgene: Honoraria; Novartis: Honoraria; Roche: Honoraria; Gilead: Honoraria.